Interpace Diagnostics Group (IDXG) AI Stock Analysis

• Market Cap: $4.87M
• Dividend Yield: N/A
• Average Volume (3M): 6.54K
• Price to Earnings (P/E): 2.1
• Beta (1Y): 1.30
• Revenue Growth: 9.06%
• EPS Growth: 31.06%
• Country: US
• Employees: 111
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.14
• Shares Outstanding: 4,423,093
• 10 Day Avg. Volume: 9,416
• 30 Day Avg. Volume: 6,542
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.23
• Enterprise Value/Revenue: 0.13
• Enterprise Value/Gross Profit: 0.21
• Enterprise Value/Ebitda: 0.91
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 74 Outperform
• Price Target: $1.00 ▲(6.38% Upside)

Interpace Diagnostics Group's stock is rated favorably due to its strong technical indicators and attractive valuation. The financial performance shows positive trends, but the negative equity remains a concern. The stock's bullish momentum and undervaluation are the most significant factors contributing to the high score.

Interpace Diagnostics Group Business Overview & Revenue Model

Company Description

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

How the Company Makes Money

Interpace Diagnostics Group generates revenue primarily through the sale of its diagnostic tests and associated services. The company charges healthcare providers for its molecular diagnostic tests, which are often reimbursed by insurance companies. Key revenue streams include test orders from hospitals, laboratories, and physicians, as well as partnerships with healthcare organizations that enhance its market reach. Additionally, IDXG may benefit from collaborations with pharmaceutical companies for companion diagnostics, which can further contribute to its earnings.

Interpace Diagnostics Group Financial Statement Overview

Summary

Interpace Diagnostics Group shows strong revenue growth and profitability improvements, with a significant increase in cash flow. However, the negative equity on the balance sheet poses a risk to long-term stability, necessitating careful management.

Income Statement

Interpace Diagnostics Group has shown a significant improvement in its income statement metrics over the recent years. The gross profit margin for 2024 stands at 63.8%, reflecting efficient cost management. The net profit margin improved to 14.3%, indicating strong profitability. Revenue growth rate from 2023 to 2024 was 16.7%, showing solid growth momentum. The EBIT margin of 17.3% and EBITDA margin of 17.8% for 2024 suggest robust operating performance. Overall, the income statement reveals a positive growth trajectory and improved profitability.

Balance Sheet

The balance sheet shows ongoing financial challenges, with a negative stockholders' equity of -$2.2 million in 2024, indicating potential solvency issues. However, the company has reduced its debt levels significantly over time, with a debt-to-equity ratio improvement as total debt decreased to $1.18 million. Return on equity is not meaningful due to negative equity. The equity ratio remains negative, further emphasizing balance sheet weaknesses. Improvements in reducing debt and liabilities are positive steps, but negative equity poses risks.

Cash Flow

Cash flow analysis highlights a strong recovery in cash generation capabilities. The operating cash flow in 2024 was $4.65 million, significantly higher than in previous years. Free cash flow improved to $3.77 million, indicating better cash management. The free cash flow growth rate from 2023 to 2024 is 13.6%, showcasing effective capital allocation. The operating cash flow to net income ratio of 0.69 indicates efficient cash conversion. Overall, the cash flow statement reflects positive trends in liquidity and cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	45.36M	46.93M	40.21M	31.84M	41.31M	32.40M
Gross Profit	29.07M	29.93M	23.90M	18.23M	17.95M	10.72M
EBITDA	6.54M	8.36M	3.84M	-2.27M	-1.33M	-20.10M
Net Income	5.18M	6.70M	802.00K	-5.87M	-14.75M	-26.20M
Balance Sheet
Total Assets	12.34M	14.79M	13.02M	15.98M	38.43M	45.68M
Cash, Cash Equivalents and Short-Term Investments	502.00K	1.46M	3.50M	4.83M	3.31M	2.77M
Total Debt	3.15M	5.86M	11.19M	16.09M	13.72M	4.74M
Total Liabilities	13.55M	17.01M	28.16M	79.05M	80.84M	74.76M
Stockholders Equity	-1.21M	-2.22M	-15.14M	-63.07M	-42.42M	-29.08M
Cash Flow
Free Cash Flow	4.20M	3.77M	3.32M	-8.01M	-9.07M	-16.15M
Operating Cash Flow	5.05M	4.65M	3.79M	-7.69M	-8.72M	-14.58M
Investing Cash Flow	-852.00K	-876.00K	-87.00K	6.21M	-315.00K	-1.57M
Financing Cash Flow	-5.72M	-5.81M	-5.03M	3.00M	8.98M	16.61M

Interpace Diagnostics Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.94
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDXG, the sentiment is Positive. The current price of 0.94 is below the 20-day moving average (MA) of 0.95, above the 50-day MA of 0.89, and below the 200-day MA of 0.95, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 65.50 is Neutral, neither overbought nor oversold. The STOCH value of 88.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDXG.

Interpace Diagnostics Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IDXG	―	$4.87M	2.09	―	―	9.06%	31.06%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYNZ	―	$8.61M	―	―	―	―	―
INBS	―	$8.63M	―	-186.64%	―	-1.90%	87.72%
BIAF	―	$12.96M	―	-1802.45%	―	4.99%	22.58%
NDRA	―	$5.84M	-0.01	-167.48%	―	―	77.66%
CHEK	―	$10.18M	―	―	―	―	―

Interpace Diagnostics Group Corporate Events

Interpace Biosciences Reports Q2 2025 Earnings

Interpace Biosciences, Inc. is a company specializing in molecular diagnostics, bioinformatics, and pathology services, primarily focused on cancer risk evaluation using advanced technology in personalized medicine. In its latest earnings report for the quarter ended June 30, 2025, Interpace Biosciences reported a decline in revenue compared to the previous year, with net revenue at $9.2 million, down from $12.0 million. Despite this, the company managed to achieve a gross profit of $5.3 million, although it faced a net loss of $640,000 for the quarter. Key financial metrics highlighted in the report include a decrease in cash and cash equivalents to $502,000 from $1.5 million at the end of 2024, and a reduction in total liabilities from $17.0 million to $13.5 million. The company also implemented a restructuring plan due to the loss of Medicare coverage for its PancraGEN test, which led to workforce reductions and cost-saving measures. Looking ahead, Interpace Biosciences plans to address its capital needs through improved margins, cost containment, and exploring additional funding options. The management remains focused on navigating the challenges posed by recent changes in reimbursement coverage and aims to sustain operations through strategic adjustments.